Clinical trials: Hemodialysis
Secondary Hyperparathyroidism
Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder
The purpose of this study is to evaluate the effect of thrice weekly intravenous (IV) administration of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney…
- Trial name
- NCT01414114
- Testing
- Etelcalcetide
- Volunteers
- 37 people
- Sponsor
- KAI Pharmaceuticals
Anemia, Chronic Renal Failure
Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA
The purpose of this study is to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease who are on dialysis and are not taking any treatment to increase their red…
- Conditions
- Anemia, Chronic Renal Failure, Chronic Kidney Disease
- Trial name
- NCT00680043
- Testing
- peginesatide, Epoetin Alfa
- Where
- 11 sites in Russia
- Volunteers
- 114 people
- Sponsor
- Affymax
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
- Trial name
- NCT00037635
- Testing
- AMG 073
- Volunteers
- 400 people
- Sponsor
- Amgen
Renal Impairment
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.
- Trial name
- NCT06318676
- Testing
- Mezigdomide
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Celgene
Secondary Hyperparathyroidism
Phase 3 Study of KHK7580
The purpose of this study is to evaluate the efficacy and safety of KHK7580 orally administered once daily for 30 weeks in subjects with secondary hyperparathyroidism (SHPT) receiving hemodialysis in a randomized, double-blind…
- Trial name
- NCT02549391
- Testing
- KHK7580, KRN1493
- Where
- Japan
- Volunteers
- 634 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Uremic Pruritus
A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)
Primary objective of this multicenter, double-blind, placebo controlled, randomized withdrawal study are to determine the effectiveness and safety of orally administered AC-820 in doses of 2.5 µg and 5.0 µg daily in patients with…
- Trial name
- AC120-8231 (NCT00793156)
- Testing
- Nalfurafine HCl 2.5 µg, Nalfurafine HCl 5.0 µg
- Volunteers
- 350 people
- Sponsor
- Acologix, Inc.
Peripheral Arterial Disease, Fistula
A Study of Hemodialysis Arteriovenous Fistulae Stenosis Treated With APERTO
To evaluate the safety and efficacy of Paclitaxel Eluting Hemodialysis Shunt Balloon Dilatation Catheter (APERTO) compared with the Balloon Dilatation catheter (OHICHO II) for the treatment of Arteriovenous Fistulae Stenosis in…
- Trial name
- NCT02962141
- Testing
- Paclitaxel Releasing Peripheral Balloon Dilatation Catheter, Balloon Dilatation Catheter
- Where
- 9 sites in China
- Volunteers
- 161 people
- Sponsor
- ZhuHai Cardionovum Medical Device Co., Ltd.
End Stage Renal Disease
Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts
The purpose of this study is to establish the substantial equivalence of Expedial and ePTFE grafts for effectiveness in maintaining primary or assisted primary patency.
- Trial name
- NCT00131872
- Testing
- Expedial Vascular Access Graft
- Where
- 8 sites in United States
- Volunteers
- 172 people
- Sponsor
- LeMaitre Vascular
Dialysis, Anemia
Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment
The purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with end-stage renal disease who recently started dialysis.
- Trial name
- NCT01414075
- Testing
- Roxadustat, Oral Iron, IV Iron
- Where
- 7 sites in United States, Hong Kong and 2 more
- Volunteers
- 60 people
- Sponsor
- Kyntra Bio
Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis
Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
The purpose of this survey is to evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
- Trial name
- NCT01901107
- Testing
- Kiklin capsules
- Where
- 8 sites in Japan
- Volunteers
- 1,078 people
- Sponsor
- Astellas Pharma Inc
Anemia
Assesment of a Predictive Model Dosage of EPO in Hemodialysis Patients
Assesment of a predictive model of anemia management: Dosage of erythropoietin (EPO) and Iron adminsitration in hemodialysis patients.
- Trial name
- NCT02337335
- Where
- Spain
- Volunteers
- 268 people
- Sponsor
- NephroCare Spain
Chronic Kidney Disease, End Stage Renal Disease
Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease
The purpose of this open-label extension study is to evaluate long-term efficacy and safety of roxadustat in maintaining hemoglobin (Hb) in participants with dialysis and non-dialysis chronic kidney disease (CKD) who have…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Anemia
- Trial name
- NCT01630889
- Testing
- Roxadustat
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 15 people
- Sponsor
- Kyntra Bio
End Stage Renal Disease
Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
The purpose of this study is to compare the immune response to HEPLISAV™ booster injection with the immune response to Engerix-B® and Fendrix® booster vaccinations among patients with end stage renal disease (ESRD) on…
- Trial name
- NCT01195246
- Testing
- HEPLISAV, Engerix-B, Fendrix
- Where
- 19 sites in Germany
- Volunteers
- 155 people
- Sponsor
- Dynavax Technologies Corporation
Chronic Kidney Disease
Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate
This is a double-blind, randomized, cross-over study conducted at centers within the United States. The study consists of five periods: an up to two-week Screening Period, a 5-week Run-In Period, two eight-week study treatment…
- Trial name
- NCT00440648
- Testing
- sevelamer carbonate, sevelamer hydrochloride, sevelamer hydrochloride, sevelamer carbonate
- Where
- 15 sites in United States
- Volunteers
- 80 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Kidney Disease
Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis
This study will determine the titration regimen for SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Asian Chronic Kidney Disease patients on hemodialysis
- Trial name
- SBR759 (NCT00704678)
- Testing
- SBR759, Sevelamer HCl
- Where
- 15 sites in Japan, Taiwan
- Volunteers
- 203 people
- Sponsor
- Novartis Pharmaceuticals
End Stage Renal Disease
Comparison of Individualized Sodium Management Versus Standard Treatment in Hemodialysis
The SODIAH study is designed with the aim to assess the impact of isonatremic dialysis on interdialytic weight gain, fluid status, intradialytic hemodynamic stability, and incidence of intradialytic morbid events in dialysis…
- Trial name
- SODIAH (NCT06341452)
- Testing
- Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control
- Where
- Czechia
- Volunteers
- 130 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Stenoses
Pivotal Study for the FLAIR Endovascular Stent Graft
This study compared the FLAIR™ Endovascular Stent Graft to balloon angioplasty in patients with stenoses at the venous anastomosis of a synthetic AV access graft.
- Trial name
- NCT00678249
- Testing
- FLAIR Endovascular Stent Graft, PTA
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- C. R. Bard
Sudden Cardiac Death, Sudden Cardiac Arrest
Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study
A multi-center, prospective, randomized controlled clinical trial with 1:1 assignment of treatment and control. This study will evaluate the impact of wearable cardioverter defibrillator use on sudden cardiac death in incident…
- Trial name
- WED-HED (NCT02481206)
- Testing
- Wearable Cardioverter Defibrillator
- Where
- 31 sites in United States
- Volunteers
- 66 people
- Sponsor
- Zoll Medical Corporation
Renal Failure Chronic Requiring Hemodialysis
Performance Comparison of Revaclear With Larger Dialyzer
The purpose of the study is to show equivalent performance of the Revaclear dialyzer when compared to a dialyzer with larger membrane surface area.
- Trial name
- Revacom HD (NCT01722695)
- Testing
- Dialyzer comparison
- Where
- 2 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Vantive Health LLC
End Stage Renal Disease
A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis
Malnutrition and altered protein catabolism are serious problems in renal failure and hemodialysis (HD) patients. The purpose of this study is to characterize the safety of GHRP-1/AG in subjects with ESRD on HD; to characterize…
- Trial name
- NCT00381602
- Testing
- GHRP-1/AG 70 mg depot in ESRD
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- QLT Inc.